Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ligand Pharmaceuticals, Inc shares valued at $57,271 were sold by Reardon Andrew on Jun 10 ’25. At $114.54 per share, Reardon Andrew sold 500 shares. The insider’s holdings dropped to 32,403 shares worth approximately $3.71 million following the completion of this transaction.
Also, ANDREW THOMAS REARDON purchased 500 shares, netting a total of over 57,271 in proceeds.
Before that, Reardon Andrew had sold 1,000 shares from its account. In a trade valued at $104,000, the CLO & Secretary traded Ligand Pharmaceuticals, Inc shares for $104.00 each. Upon closing the transaction, the insider’s holdings decreased to 1,000 shares, worth approximately $3.77 million.
As published in their initiating research note from Stifel on April 10, 2025, Ligand Pharmaceuticals, Inc [LGND] has been a Buy and the price target has been revised to $143. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early October. As of July 30, 2024, RBC Capital Mkts has initiated its “an Outperform” rating for LGND.
Analyzing LGND Stock Performance
On last trading session,, Ligand Pharmaceuticals, Inc [NASDAQ: LGND] rose 1.87% to $114.64. During the last five days, there has been a drop of approximately -0.65%. Over the course of the year, Ligand Pharmaceuticals, Inc shares have jumped approximately 6.99%. Shares of the company reached a 52-week high of $125.17 on 03/03/25 and a 52-week low of $93.58 on 04/09/25.
Support And Resistance Levels for Ligand Pharmaceuticals, Inc (LGND)
According to the 24-hour chart, there is a support level at 112.58, which, if violated, would cause prices to drop to 110.51. In the upper region, resistance lies at 116.12. The next price resistance is at 117.60. RSI (Relative Strength Index) is 64.00 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Ligand Pharmaceuticals, Inc (LGND)?
In terms of Ligand Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 155 in the next 12 months, up nearly 37.73% from the previous closing price of $112.54. Analysts anticipate Ligand Pharmaceuticals, Inc stock to reach 155 by 2025, with the lowest price target being 155. In spite of this, 5 analysts ranked Ligand Pharmaceuticals, Inc stock as Buy at the end of 2025. On February 04, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $310.
